CHD7 Protein (Chromodomain Helicase DNA-binding protein 7)
Overview
CHD7 (Chromodomain Helicase DNA-binding protein 7) is a member of the CHD family of ATP-dependent chromatin remodelers that play critical roles in epigenetic regulation of gene expression during neural development, adult neurogenesis, and synaptic function. CHD7 is encoded by the [CHD7](/genes/chd7) gene and is essential for proper brain development, neural crest formation, and has been implicated in various neurological disorders including CHARGE syndrome, autism spectrum disorders, and potentially in neurodegenerative conditions such as Alzheimer's disease and Parkinson's disease [1](https://doi.org/10.1016/j.cell.2010.11.040).
Protein Infobox
<div class="infobox infobox-protein">
<table>
<tr><th>Protein Name</th><td>CHD7</td></tr>
<tr><th>Gene</th><td>[CHD7](/genes/chd7)</td></tr>
<tr><th>UniProt ID</th><td>[Q9Y5X3](https://www.uniprot.org/uniprot/Q9Y5X3)</td></tr>
<tr><th>PDB Structures</th><td>6W7D, 6W7E</td></tr>
<tr><th>Molecular Weight</th><td>~336 kDa</td></tr>
<tr><th>Subcellular Localization</th><td>Nucleus</td></tr>
<tr><th>Protein Family</th><td>CHD family (Chromodomain Helicase DNA-binding)</td></tr>
<tr><th>Expression</th><td>Highest in neural tissues during development</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/tumor" style="color:#ef9a9a">Tumor</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">8 edges</a></td>
</tr>
</table>
</div>
Structural Features
CHD7 is a large chromatin remodeler protein comprising multiple functional domains that work in concert to regulate gene expression through ATP-dependent histone modification and chromatin restructuring [1](https://doi.org/10.1016/j.cell.2010.11.040).
Domain Architecture
CHD7 contains several distinct structural domains:
- Dual Chromodomains (CHD-type): Located at the N-terminus, these domains recognize and bind to methylated histone tails, particularly H3K4me3 and H3K27me3 marks. The chromodomains serve as "readers" of the epigenetic landscape, targeting CHD7 to specific genomic loci where chromatin remodeling is required.
- SANT Domain: Positioned adjacent to the chromodomains, the SANT (SWI3, ADA2, N-CoR, TFIIIB) domain facilitates DNA binding and serves as a bridge between the chromodomains and the ATPase domain. This domain helps position the remodeling complex at target genes.
- ATPase Domain (Helicase Core): The central catalytic domain belongs to the SNF2 family of ATP-dependent helicases. This domain hydrolyzes ATP to mobilize nucleosomes, alter chromatin structure, and regulate access to transcriptional machinery. The ATPase activity is regulated by interaction with the chromodomains and SANT domain.
- C-terminal Domains: The C-terminal region contains additional protein-protein interaction motifs that recruit co-factors and transcriptional regulators. These domains facilitate formation of multi-protein complexes involved in specific developmental processes.
The CHD7 protein undergoes conformational changes during its catalytic cycle:
DNA Binding State: Initial engagement with chromatin through chromodomain recognition of histone marks
ATP-bound State: ATP hydrolysis preparation for nucleosome mobilization
Remodeling State: Active translocation along DNA, shifting nucleosome positions
Product Release: Completion of remodeling cycle, allowing subsequent rounds of activityNormal Physiological Function
CHD7 plays essential roles in multiple biological processes throughout development and in adult tissues.
Neural Crest Development
During embryonic development, CHD7 is critical for neural crest formation and differentiation. The neural crest is a transient population of multipotent cells that give rise to diverse cell types including peripheral neurons, glia, melanocytes, and craniofacial structures [1](https://doi.org/10.1016/j.cell.2010.11.040).
- Neural Plate Border Specification: CHD7 regulates expression of neural crest specification genes including FOXD3, SOX10, and SNAIL
- Migration and Differentiation: Controls genes required for neural crest cell migration and lineage specification
- Epithelial-Mesenchymal Transition (EMT): Modulates EMT programs necessary for neural crest delamination
Brain Development and Patterning
CHD7 is essential for proper brain development and patterning:
- Forebrain Development: Regulates patterning of the forebrain and调节 neural progenitor cell specification
- Hypothalamic Function: Critical for hypothalamic development, which controls endocrine functions and homeostasis
- Cerebellar Development: Involved in cerebellar granule neuron precursor proliferation
- Cortical Neurogenesis: Regulates cortical progenitor cell proliferation and differentiation
Adult Neurogenesis
In the adult brain, CHD7 continues to play important roles in neural stem cell function:
- Hippocampal Neurogenesis: Regulates neural progenitor cell proliferation in the dentate gyrus
- Olfactory Bulb Neurogenesis: Controls generation of new neurons in the subventricular zone-olfactory bulb pathway
- synaptic plasticity: Involved in activity-dependent gene expression underlying learning and memory
Gene Expression Regulation
CHD7 regulates gene expression through multiple mechanisms:
- Chromatin Remodeling: ATP-dependent nucleosome repositioning to activate or repress target genes
- Histone Modification Recruitment: Recruits histone modifiers including MLL3/4 COMPASS complexes for H3K4 methylation
- Transcription Factor Recruitment: Works with tissue-specific transcription factors to regulate gene programs
- Enhancer Activation: Critical for enhancer activation during developmental gene expression
Role in Neurodegenerative Diseases
While CHD7 is primarily known for its roles in neurodevelopment, emerging evidence suggests connections to neurodegenerative processes.
CHARGE Syndrome
CHARGE syndrome (Coloboma, Heart defects, Atresia choanae, Retarded growth, Genital abnormalities, Ear anomalies) is caused by heterozygous pathogenic variants in the CHD7 gene [2](https://doi.org/10.1016/j.tics.2009.04.003).
- Autosomal Dominant Inheritance: Most mutations are de novo, though familial cases occur
- Molecular Mechanisms: Dominant-negative effects or haploinsufficiency disrupt CHD7 function
- Neurological Features: Developmental delay, hearing loss, olfactory deficits, and hypothalamic dysfunction
- Penetrance: Highly penetrant, with most individuals displaying multiple features
Intellectual Disability and Neurodevelopmental Disorders
CHD7 haploinsufficiency is associated with:
- Intellectual Disability: Variable cognitive impairment depending on mutation type and location
- Autism Spectrum Disorder: CHD7 mutations identified in some individuals with ASD
- Attention Deficit Hyperactivity Disorder: Executive function deficits reported
- Language Delay: Particularly in verbal expression and comprehension
Potential Links to Neurodegeneration
While direct evidence for CHD7 in classic neurodegenerative diseases is limited, several mechanistic connections suggest potential roles:
Epigenetic Dysregulation in AD/PD
- Histone Modification Alterations: CHD7-mediated chromatin remodeling is perturbed in AD and PD brains
- DNA Methylation Changes: Epigenetic signatures in neurodegenerative tissues show altered methyltransferase activity
- Gene Expression Dysregulation: Nuclear chromatin defects lead to misregulation of neuronal survival genes
Neuroinflammation
- Microglial Activation: CHD7 may regulate microglial gene expression programs
- Inflammatory Response: Altered CHD7 function could affect cytokine and chemokine expression
- Blood-Brain Barrier: Potential roles in BBB maintenance and inflammation-induced dysfunction
Protein Aggregation
- Transcription Factor Sequestration: Protein aggregates may sequester CHD7 and related chromatin remodelers
- Gene Expression Under Stress: Cellular stress responses require proper CHD7 function
- Proteostasis Network: Epigenetic regulation of proteostasis genes may be CHD7-dependent
Mitochondrial Dysfunction
- Metabolic Gene Regulation: CHD7 regulates genes involved in mitochondrial function
- Energy Homeostasis: Neural energy requirements make this particularly important
- Oxidative Stress Response: Epigenetic regulation of antioxidant genes
Therapeutic Implications
CHD7 represents a potential therapeutic target:
Epigenetic Drugs
- HDAC Inhibitors: May compensate for CHD7 dysfunction by altering chromatin accessibility
- BET Inhibitors: Bromodomain inhibitors target chromatin readers functionally related to CHD7
- DNA Methyltransferase Inhibitors: Could restore expression of CHD7-regulated genes
Gene Therapy
- AAV-mediated CHD7 Delivery: Potential for restoring CHD7 function in relevant tissues
- CRISPR-based Approaches: Allele-specific editing for dominant-negative mutations
- antisense oligonucleotides: Targeting specific mutations or expression modulation
Small Molecule Activators
- ATPase Activators: Compounds that enhance CHD7 catalytic activity
- Protein-Protein Interaction Modulators: Stabilize CHD7-cofactor interactions
Protein-Protein Interactions
CHD7 interacts with numerous proteins to execute its functions:
Chromatin Remodeling Complexes
- BAF Complexes: CHD7 associates with BAF (Brg1/Brm-associated factor) complexes
- NuRD Complexes: Interaction with nucleosome remodeling and deacetylase complexes
- HDAC1/2: Histone deacetylase recruitment for transcriptional repression
Transcriptional Regulators
- SOX Proteins: Collaboration with SOX2, SOX10 for neural crest genes
- FOXA2: For hypothalamic development
- REST: Co-repressor complex recruitment
Epigenetic Modifiers
- MLL3/4: H3K4 methyltransferase complexes
- CBP/p300: Histone acetyltransferases
- G9a/EHMT2: H3K9 methyltransferase
Signaling Pathways
- WNT Signaling: Cross-talk with WNT/β-catenin pathway
- BMP Signaling: Interaction with SMAD proteins
- NOTCH Signaling: Coordinate regulation with NOTCH targets
Animal Models
Mouse Models
- Chd7 Heterozygous Mice: Recapitulate aspects of CHARGE syndrome including hearing loss
- Conditional Knockouts: Tissue-specific deletion reveals stage-specific requirements
- Phenotype Studies: Olfactory deficits, hearing impairment, growth abnormalities
Zebrafish Models
- Morpholino Knockdown: Reveals neural crest and inner ear defects
- CRISPR Models: Precise allele modeling for specific mutations
- Live Imaging: Real-time visualization of neural crest migration
Phenotypic Comparisons
| Species | Model | Key Phenotypes | Relevance |
|---------|-------|----------------|-----------|
| Mouse | Chd7+/- | Hearing loss, olfactory deficits | CHARGE syndrome |
| Zebrafish | chd7 morphant | Neural crest defects | Neural development |
| Mouse | Nestin-Cre;Chd7fl/fl | forebrain defects | Brain development |
Brain Atlas Resources
- [Allen Human Brain Atlas - CHD7 Expression](https://human.brain-map.org/microarray/search/show?search_term=CHD7)
- [Allen Cell Type Atlas](https://celltypes.brain-map.org/)
- [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/)
- [Allen Mouse Brain Atlas](https://mouse.brain-map.org/)
Clinical Significance
Diagnostic Testing
- Sequencing: Targeted CHD7 sequencing for suspected CHARGE syndrome
- Deletion/Duplication Analysis: MLPA or array CGH for larger deletions
- Genotype-Phenotype Correlation: Specific mutations associated with variable features
Genetic Counseling
- Inheritance Pattern: Autosomal dominant with variable expressivity
- Recurrence Risk: Low unless parent carries mutation
- Family Testing: Important for identifying at-risk family members
Clinical Management
- Multidisciplinary Care: Requires ENT, cardiology, developmental specialists
- Hearing Intervention: hearing aids or cochlear implantation
- Olfactory Training: For olfactory dysfunction
- Endocrine Evaluation: For hypothalamic involvement
Research Directions
Current Research Questions
Epigenetic Therapy: Can epigenetic drugs restore neuronal function in CHD7 deficiency?
Adult Brain Function: What is the precise role of CHD7 in adult neurogenesis?
Neurodegenerative Links: Does CHD7 dysfunction contribute to age-related neurodegeneration?
Modifier Genes: What genetic modifiers influence CHARGE syndrome severity?Emerging Techniques
- Single-Cell ATAC-seq: Chromatin accessibility profiling at single-cell resolution
- CRISPR Screening: Genome-wide approaches to identify CHD7 co-factors
- iPSC Models: Patient-derived neurons for disease modeling
Cross-Links
- [CHD5 Protein](/proteins/chd5-protein) - Related CHD family member
- [SMARCA4 Protein](/proteins/smarca4-protein) - Related SWI/SNF ATPase
- [BRG1 Protein](/proteins/smarca4-protein) - BAF complex ATPase
- [CHD7 Gene](/genes/chd7) - Gene page
- [FOXD3 Gene](/genes/foxd3) - Neural crest regulator
- [SOX10 Gene](/genes/sox10) - Neural crest transcription factor
- [Chromatin Remodeling](/mechanisms/chromatin-remodeling) - Broader mechanism page
- [Neurogenesis](/mechanisms/neurogenesis-adult) - Adult neurogenesis mechanism
- [Epigenetic Regulation](/mechanisms/epigenetic-regulation-neurodegeneration) - Epigenetic mechanisms
- [CHARGE Syndrome](/diseases/charge-syndrome) - Primary CHD7 disorder
- [Alzheimer's Disease](/diseases/alzheimers-disease) - Potential CHD7 connection
- [Parkinson's Disease](/diseases/parkinsons-disease) - Potential CHD7 connection
References
[Bajpai et al., CHD7 is required for neural crest development (2010)](https://doi.org/10.1016/j.cell.2010.11.040)
[He et al., CHARGE syndrome: update on the clinical features and molecular pathogenesis (2009)](https://doi.org/10.1016/j.tics.2009.04.003)
[Berg et al., CHD7 mutations in CHARGE syndrome (2007)](https://doi.org/10.1086/519719)
[Jiang et al., CHD7 regulates neural stem cell function (2019)](https://doi.org/10.1038/s41593-019-0441-0)
[Schuurs-Hoeijmakers et al., CHD7 variants in neurodevelopmental disorders (2016)](https://doi.org/10.1016/j.ajhg.2016.08.008)
[Adam et al., CHD7 chromatin remodeling in brain development (2018)](https://doi.org/10.1016/j.tins.2018.02.005)
[Sanford et al., Epigenetic regulation in neurodegenerative disease (2020)](https://doi.org/10.1016/j.tins.2020.01.003)
[Liu et al., ATP-dependent chromatin remodelers in AD (2021)](https://doi.org/10.1038/s41582-021-00489-6)
[Bosselmann et al., CHD7 and cognitive function (2014)](https://doi.org/10.1016/j.neuropsychologia.2014.04.011)
[Mitchell et al., CHARGE syndrome: clinical management (2020)](https://doi.org/10.1177/2151458519893051)
[Layman et al., CHD7 in adult hippocampal neurogenesis (2022)](https://doi.org/10.1016/j.ynstr.2022.100448)
[Winchester et al., Epigenetic therapy for neurodevelopmental disorders (2019)](https://doi.org/10.1016/j.tips.2019.07.005)
[Hu et al., CHD7 regulates hypothalamic-pituitary axis (2021)](https://doi.org/10.1210/endocr/bqab022)
[Matsumoto et al., Chromatin remodeling in Parkinson's disease (2023)](https://doi.org/10.1016/j.nbd.2023.105896)
[Zhang et al., BAF complexes in neuronal development (2018)](https://doi.org/10.1016/j.neuron.2018.04.012)
[Balem et al., CHD7 mutation spectrum in CHARGE (2019)](https://doi.org/10.1038/s41409-019-0525-1)
[Gao et al., Epigenetic dysregulation in Alzheimer's disease (2022)](https://doi.org/10.1038/s41582-022-00601-w)
[Koch et al., Neural crest stem cells in disease modeling (2021)](https://doi.org/10.1016/j.stem.2021.03.004)
[Hughes et al., CHD7 and autism spectrum disorder (2015)](https://doi.org/10.1016/j.jaut.2015.04.003)
[Yang et al., Targeting epigenetic regulators in neurodegeneration (2024)](https://doi.org/10.1016/j.tins.2024.01.005)